

POSTER PRESENTATION

Open Access

Discovery of novel α -amylase inhibitors using structure-based drug design

Jamil Al-Asri*, Gerhard Wolber

From 9th German Conference on Chemoinformatics
Fulda, Germany. 10-12 November 2013

α -Amylase is an endoamylase and belongs to glycoside hydrolase family 13 (GH 13) according to the classification of carbohydrate-active enzymes [1]. It initiates starch hydrolysis into smaller oligomers. Inhibitors of this enzyme are of pharmacological importance as α -amylase is considered as attractive target for treating elevated post-prandial blood glucose levels resulting in obesity and type II diabetes. Besides the application as a drug, it is highly interesting to classify nutritional components, such as food additives or secondary plant metabolites with respect to their modulation of α -amylase.


We present a model that predicts the affinity of small organic molecules to α -amylase. On the basis of available crystal structures (Figure 1) [2], we developed a virtual screening workflow for the identification of novel non-peptidic, non-carbohydrate α -amylase inhibitors. In

addition to virtual screening using structure-based 3D pharmacophore models [3], molecular docking and clustering for diversity selection have been applied as post-screening filters. Fourteen virtual hits were purchased and tested in vitro using a kinetic assay with p-Nitrophenyl- α -d-maltopentaoside (PNPG5) as a chromogenic substrate. Three of those fourteen compounds showed concentration-dependent inhibition with promising IC_{50} values (hit rate: 21%).

Published: 11 March 2014

References

1. Cantarel BL, Coutinho PM, Rancurel C, Bernard T, Lombard V, Henrissat B: The carbohydrate-active enzymes database (cazy): An expert resource for glycogenomics. *Nucleic Acids Res* 2009, **37**:D233-D238.
2. Qin X, Ren L, Yang X, Bai F, Wang L, Geng P, Bai G, Shen Y: Structures of human pancreatic alpha-amylase in complex with acarviosatins:



* Correspondence: jmasa75@zedat.fu-berlin.de
Computer-Aided Molecular Design, Pharmaceutical Chemistry Department,
Freie Universität Berlin, Berlin, 14195, Germany

Implications for drug design against type II diabetes. *J Struct Biol* 2011, **174**(1):196-202.

3. Wolber G, Langer T: Ligandscout: 3-d pharmacophores derived from protein-bound ligands and their use as virtual screening filters. *J Chem Inf Model* 2005, **45**(1):160-169.

doi:10.1186/1758-2946-6-S1-P50

Cite this article as: Al-Asri and Wolber: Discovery of novel α -amylase inhibitors using structure-based drug design. *Journal of Cheminformatics* 2014 **6**(Suppl 1):P50.

Publish with **ChemistryCentral** and every scientist can read your work free of charge

“Open access provides opportunities to our colleagues in other parts of the globe, by allowing anyone to view the content free of charge.”

W. Jeffery Hurst, The Hershey Company.

- available free of charge to the entire scientific community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
<http://www.chemistrycentral.com/manuscript/>

